Liu Wen, Han Yinlian, Liu Yuqian, Tian Min, Liu Heyin, Yang Yang, Liu Jinde, Song Chengyuan, Liu Yiming
Department of Neurology, Qilu Hospital of Shandong University, Jinan, China.
J Neurol. 2025 May 2;272(5):369. doi: 10.1007/s00415-025-13086-0.
Orthostatic hypotension (OH) is not rare in patients with Parkinson's disease (PD). To date, there have been few studies on the association of genetic variants with OH.
We aimed to evaluate the association of LRRK2 and GBA variants with OH in a large PD cohort.
This study utilized data from the PPMI database, including 863 participants who were divided into the sporadic PD patients (sPD, n = 357), GBA variant carriers (GBA-PD, n = 137), LRRK2 variant carriers (LRRK2-PD, n = 158) and healthy controls (HC, n = 211). LRRK2-PD patients were additionally categorized into G2019S (n = 141) and R1441G (n = 16). GBA-PD patients were categorized into three subgroups by the genomic categorization.
No significant difference was found in the incidence of OH among the four groups at baseline. Lower University of Pennsylvania Scent Identification Test (UPSIT) scores, higher Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ) score and the risk GBA mutations were significantly associated with OH cross-sectionally. Higher Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total and part II scores, higher Epworth Sleepiness Scale (ESS) scores, higher RBDSQ scores and higher Scales for Outcomes in Parkinson's Disease-Autonomic Questionnaire (SCOPA-AUT) scores were strongly linked with OH progression over time. LRRK2 mutations especially LRRK2 G2019S mutation were significantly associated with the lower risk of OH progression.
LRRK2-PD, particularly the LRRK2-G2019S-PD, were found to have a lower risk of OH. In contrast, the role of GBA mutations in OH appears more complex, with no further evidence to suggest that GBA is associated with the progression of OH in PD.
直立性低血压(OH)在帕金森病(PD)患者中并不罕见。迄今为止,关于基因变异与OH关联的研究很少。
我们旨在评估在一个大型PD队列中,富含亮氨酸重复激酶2(LRRK2)和葡萄糖脑苷脂酶(GBA)变异与OH的关联。
本研究利用了帕金森病进展标记物倡议(PPMI)数据库的数据,包括863名参与者,他们被分为散发性PD患者(sPD,n = 357)、GBA变异携带者(GBA-PD,n = 137)、LRRK2变异携带者(LRRK2-PD,n = 158)和健康对照(HC,n = 211)。LRRK2-PD患者进一步分为G2019S(n = 141)和R1441G(n = 16)亚组。GBA-PD患者根据基因分型分为三个亚组。
四组在基线时OH的发生率无显著差异。宾夕法尼亚大学嗅觉识别测试(UPSIT)得分较低、快速眼动睡眠行为障碍筛查问卷(RBDSQ)得分较高以及GBA风险突变与OH的横断面显著相关。较高的运动障碍协会统一帕金森病评定量表(MDS-UPDRS)总分和第二部分得分、较高的爱泼华嗜睡量表(ESS)得分、较高的RBDSQ得分以及较高的帕金森病自主神经症状问卷(SCOPA-AUT)得分与OH随时间的进展密切相关。LRRK2突变尤其是LRRK2 G2019S突变与OH进展风险较低显著相关。
发现LRRK2-PD,尤其是LRRK2-G2019S-PD,发生OH的风险较低。相比之下,GBA突变在OH中的作用似乎更为复杂,没有进一步证据表明GBA与PD中OH的进展相关。